NASDAQ: OCS - Oculis Holding AG

Yield per half year: +44.65%
Sector: Healthcare

Share chart Oculis Holding AG

Extended chart Simple chart
Financial Markets by TradingView

About

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.

more details
The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2023-03-02
ISIN CH1242303498
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета chf
Сайт https://oculis.com
Цена ао 12.65
Change price per day: -0.6444% (17.07)
Change price per week: -0.1178% (16.98)
Change price per month: +4.95% (16.16)
Change price per 3 month: +37.76% (12.3116)
Change price per half year: +44.65% (11.725)
Change price per year: +51.02% (11.23)
Change price per 3 year: +74.67% (9.71)
Change price per 5 year: 0% (16.96)
Change price per 10 year: 0% (16.96)
Change price per year to date: +10.34% (15.37)
All parameters

Underestimation

Title Value Grade
P/S 317.87 1
P/BV 2.99 6
P/E 0 0
EV/EBITDA -5.31 0
Total: 3.5

Efficiency

Title Value Grade
ROA, % -77.66 0
ROE, % -94.74 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0132 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % -11.08 0
Yield Ebitda, % 277.99 10
Yield EPS, % 478.83 10
Total: 8
More

Institutions Volume Share, %
Pivotal bioVenture Partners Investment Advisor, LLC 1888788 4.66
Abrdn PLC 1452741 3.59
Nan Fung Group Holdings Limited 518933 1.28
Compagnie Lombard Odier SCmA 95750 0.24
Bank of America Corporation 16926 0.04
Searle & Co. 10000 0.02
Dupont Capital Management Corp 4 0



Head Job title Payment Year of birth
Dr. Riad Sherif M.B.A., M.D. CEO & Director N/A 1968 (57 years)
Ms. Sylvia Cheung Chief Financial Officer N/A 1975 (50 years)
Mr. Páll Ragnar Jóhannesson Chief Business Officer N/A 1982 (43 years)
Ms. Rebecca Weil Chief Commercial Officer N/A
Dr. Ramin Tadayoni M.D., Ph.D. Chief Scientific Officer N/A
Ms. Virginia R. Dean Chief Human Resources Officer N/A 1967 (58 years)
Dr. Bastian Dehmel M.D. Chief Development Officer N/A 1971 (54 years)
Dr. Snehal Shah Pharm.D. President of Research & Development N/A
Dr. Sharon Klier M.D., M.P.H. Chief Development Officer

Address: Switzerland, Zug, Bahnhofstrasse 7 - open in Google maps, open in Yandex maps
Website: https://oculis.com